Zobrazeno 1 - 10
of 16
pro vyhledávání: ''
Autor:
Mario Giuliano, Emilia Montagna, Diego D'Agostino, Sabino De Placido, Giuseppe Cancello, Monica Plaitano, Giuseppe Di Lorenzo, Michele De Laurentiis, Antonio Giordano
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines.
Autor:
Helena Hwang, Brian Z. Ring, Marshall T Schreeder, Nancy Watroba, Robert S. Seitz, Christine Murekeyisoni, Swati Kulkarni, Noel C Estopinal, Douglas T. Ross, David G. Hicks, Thaer Khoury, Rodney A. Beck
Publikováno v:
Breast Cancer Research : BCR
Introduction The addition of taxanes (Ts) to chemotherapeutic regimens has not demonstrated a consistent benefit in early-stage breast cancer. To date, no clinically relevant biomarkers that predict T response have been identified. Methods A dataset
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Autor:
Brian M Nolen, Jeffrey R Marks, Shlomo Ta'san, Alex Rand, The Minh Luong, Yun Wang, Kimberly Blackwell, Anna E Lokshin
Publikováno v:
Breast Cancer Research : BCR
Introduction Neoadjuvant chemotherapy has become the standard of care for the diverse population of women diagnosed with locally advanced breast cancer. Serum biomarker levels are increasingly being investigated for their ability to predict therapy r
Autor:
James H Dozier, Sharon Lobert, Nancy Stubbs Thomas, Laree Hiser, Hamed Benghuzzi, Michelle Tucci, Anthony Frankfurter, Jennifer A Davis, John J. Correia
Publikováno v:
Breast Cancer Research : BCR
Background Antimitotic chemotherapeutic agents target tubulin, the major protein in mitotic spindles. Tubulin isotype composition is thought to be both diagnostic of tumor progression and a determinant of the cellular response to chemotherapy. This i
Autor:
Maria García-Aranda, Teresa Téllez, Maria Luisa Hortas, Alfonso Serrano, Maximino Redondo, Maria J. Roldan, Martin E. Gleave, Miguel Morell
Publikováno v:
Breast Cancer Research : BCR
Introduction Overexpression of the apoptosis-related protein clusterin is associated with breast cancer development and tumor progression. We describe the use of clusterin-specific antisense oligonucleotides and antibodies to sensitize breast carcino
Autor:
Kosei Hirakawa, Naoki Aomatsu, Tsutomu Takashima, Katsumi Ikeda, Tetsuro Ishikawa, Masakazu Yashiro, Shinichiro Kashiwagi, Yoshinari Ogawa
Publikováno v:
Breast Cancer Research : BCR
Introduction Triple-negative breast cancer (TNBC), which is characterized by negativity for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), is a high risk breast cancer that lacks specific targets for tre
Autor:
Basileios Venizelos, V. Zobolas, J. Papadiamantis, Helen Gogas, Zoh Antonopoulou, Dimitrios Koukouras, Grigorios Xepapadakis, Urania Dafni, John Misitzis, Evagelos Tzoracoleftherakis, Christos Markopoulos
Publikováno v:
Breast Cancer Research : BCR
Introduction Extended adjuvant endocrine therapy for breast cancer with aromatase inhibitors may potentially alter the lipid profile of postmenopausal patients and thus increase the risk of developing cardiovascular disease. In this study, a subproto
Autor:
Steven A. Narod, Cezary Cybulski, Robert Chrzan, Jan Lubinski, Tomasz Huzarski, Jacek Gronwald, Andrea Eisen, Paweł Blecharz, Tomasz Byrski, Małgorzata Foszczyńska-Kłoda, Rebecca Dent, E. Marczyk
Publikováno v:
Breast Cancer Research : BCR
Introduction The purpose of this investigation was to evaluate the efficacy of cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer. Methods In a phase II, open-label study, 20 patients with metastatic breast cancer who car
Autor:
Kristjan Asgeirsson, John F.R. Robertson, Kwok L. Cheung, Claire Allen, Amit Agrawal, Ian O. Ellis, Anthony Hitch, Caroline J. Chapman
Publikováno v:
Breast Cancer Research : BCR
Background Breast tissue expression of the ERBB proto-oncogene family has been extensively studied. It was recently shown that expression of epidermal growth factor receptor (EGFR; c-erbB-1) and epidermal growth factor receptor (HER)2 (c-erbB-2) can
Publikováno v:
Breast Cancer Research
Background Lymph node status is one of the decisive prognostic factors in breast cancer. Chemotherapy targeting regional lymphatic tissues has emerged as a promising therapy for the treatment of malignancies with a high tendency to disseminate lympha